Induction immunosuppressive therapies in renal transplantation

American Journal of Health-System Pharmacy

Volumn 68, Issue 3, 2011, Pages 211-218

  Gabardi, Steven ^a,b   Martin, Spencer T ^c   Roberts, Keri L ^a   Grafals, Monica ^d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Department of Pharmacy Service ^*  (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Antibodies; Antithymocyte globulin; Basiliximab; Daclizumab; Graft rejection; Immunosuppressive agents; Muromonab CD3; Rituximab; Toxicity; Transplantation

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ANEMIA; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHILL; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; LUNG EDEMA; MAINTENANCE THERAPY; MALAISE; MICROEMULSION; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; STOMACH DISEASE; T CELL DEPLETION; TACHYCARDIA; THROMBOCYTOPENIA; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; DRUG EFFECT; GRAFT REJECTION; IMMUNOTHERAPY; METHODOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES;

EID: 79955660456     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090636     Document Type: Review

References (51)

1. Organ Procurement and Transplantation Network. Data page. http://optn.transplant.hrsa.gov/data (accessed 2010 Sep 2).
2. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs. 2005; 19:39-46. (Pubitemid 40432506)
3. Humar A, Hassoun A, Kandaswamy R et al. Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation. 1999; 68:1842-6. (Pubitemid 30027334)
4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004; 351:2715-29. (Pubitemid 39665325)
5. Norman DJ, Turka LA, eds. Primer on transplantation. 2nd ed. Mt. Laurel, NJ: American Society of Transplantation; 2001:85-102.
6. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol. 2008; 3:189-220. (Pubitemid 351488280)
7. Terasaki P, Mizutani K. Antibody mediated rejection: update 2006. Clin J Am Soc Nephrol. 2006; 1:400-3.
8. Andreoni KA, Brayman KL, Guidinger MK et al. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant. 2007; 7:1359-75.
9. Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosuppression with polyclonal antithymocyte globulins: an overview. Exp Clin Transplant. 2003; 1:79-84.
10. Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Ther. 2007; 7:1583-96. (Pubitemid 47603083)
11. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 2007; 7:137-48. (Pubitemid 46089213)
12. Vincenti F, Pace D, Birnbaum J et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant. 2003; 3:50-2. (Pubitemid 36306823)
13. Soltero L, Carbajal H, Sarkissian N et al. A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a singlecenter experience. Transplantation. 2004; 78:1560-3. (Pubitemid 39552945)
14. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006; 32:539-46. (Pubitemid 44836987)
15. Nair MP, Nampoory MR, Johny KV et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc. 2001; 33:2767-9. (Pubitemid 32725883)
16. Lin M, Ming A, Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin Transplant. 2006; 20:325-9. (Pubitemid 43880567)
17. Berard JL, Velez RL, Freeman RB et al. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy. 1999; 19:1127-37. (Pubitemid 29455934)
18. Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy. 2004; 24:1159-76. (Pubitemid 39128840)
19. Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare). Updated periodically.
20. Somerville K. Antibody agents in solid organ transplantation. J Pharm Pract. 2003; 16:388-400. (Pubitemid 38113800)
21. Kirk AD. Induction immunosuppression. Transplantation. 2006; 82:593-602. (Pubitemid 44395228)
22. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006; 26:1771-83. (Pubitemid 44885331)
23. Lopez M, Clarkson MR, Albin M et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006; 17:2844-53. (Pubitemid 44484674)
24. Goggins WC, Pascual MA, Powelson JA et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003; 76:798-802. (Pubitemid 37140222)
25. Tanriover B, Chuang P, Fishbach B et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005; 80:279-81. (Pubitemid 41061688)
26. Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999; 67:1011-8. [Erratum, Transplantation. 1999; 67:1386.]
27. Hardinger KL, Rhee S, Buchanan P et al. A prospective, randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation. 2008; 86:947-52.
28. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation. 2006; 81:1361-7. (Pubitemid 43847142)
29. Ciancio G, Burke GW 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant. 2008; 8:15-20.
30. Knechtle SJ, Fernandez LA, Pirsch JD et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery. 2004; 136:754-60. (Pubitemid 39311300)
31. Knechtle SJ, Pirsch JD, Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant. 2003; 3:722-30. (Pubitemid 36745245)
32. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant. 2005; 5: 1347-53. (Pubitemid 40839424)
33. Friend PJ, Hale G, Waldmann H et al. Campath-1M - prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation. 1989; 48:248-53. (Pubitemid 19210346)
34. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001; 1:1059-65.
35. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009; 119:2052-61.
36. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998; 351:1701-2. [Erratum, Lancet. 1998; 352: 408.]
37. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg. 2005; 200:505-15.
38. Kaufman DB, Leventhal JR, Axelrod D et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction- long-term results. Am J Transplant. 2005; 5:2539-48.
39. Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation. 2004; 78:426-33. (Pubitemid 39095410)
40. Vathsala A, Ona ET, Tan SY et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation. 2005; 80:765-74. (Pubitemid 41443758)
41. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005; 80:457-65. (Pubitemid 41209412)
42. Thomas PG, Woodside KJ, Lappin JA et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation. 2007; 83:1509-12. (Pubitemid 46934076)
43. Webster AC, Pankhurst T, Rinaldi F et al. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006; 81:953-65. (Pubitemid 43670421)
44. Gonwa T, Johnson C, Ahsan N et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 2003; 75:2048-53. (Pubitemid 36793291)
45. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant. 2002; 2:48-56.
46. Lilliu H, Brun-Strang C, Le Pen C et al. Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction. Clin Transplant. 2004; 18:247-53. (Pubitemid 38744847)
47. Mourad G, Rostaing L, Legendre C et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation. 2004; 78:584-90. (Pubitemid 39097106)
48. Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006; 355:1967-77. (Pubitemid 44708016)
49. Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs. 1999; 58:1029-42. (Pubitemid 30055045)
50. Tyden G, Genberg H, Tollemar J et al. A randomized, double-blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009; 87: 1325-9.
51. 2009 red book. Montvale, NJ: Thomson Healthcare; 2009:191-816.